Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 10 of 10 for “"CSPG4"”.
-
Photoimmunotheranostic targeting of CSPG4-positive melanoma cells using SNAP-tag technology
… directly to cancer cells expressing the CSPG4 and PD-L1 cell surface receptors. SNAP-tag is an engineered version of the human DNA repair enzyme O6-alkylguanine-DNA alkyltransferase. It reacts autocatalytically and in a strictly 1:1 coupling chemistry with substrates that have been …
-
NG2/CSPG4 Regulates Alveolar Bone and PDL Microstructure in a Sex-Dependent Manner
… alveolar bone levels (Komori et. al, 2022). NG2/CSPG4, a type I transmembrane proteoglycan that binds to type VI collagen, is expressed in mineralizing tissues such as growth plate cartilage and cranial sutures. However, its role in regulating alveolar bone density and organization remains …
-
Synthesis and biological evaluation of auristatin-F recombinant antibody-drug conjugates for cancer therapy
… chondroitin sulfate proteoglycan receptor (CSPG4) and CD44 receptors more highly expressed in various cancer types. The design and successful synthesis of two BG-linkers was followed by coupling to auristatin-F, a powerful microtubule poison, using both Cu(I)-catalysed cycloaddition and …
-
Antibody engineering to evaluate binding, internalisation, and intracellular routing of tumour-targeting fusion proteins
… specific to chondroitin sulphate proteoglycan 4 (CSPG4), a tumour-associated antigen often overexpressed in TNBC. The scFv antibody derivative was genetically fused to a SNAP-tag, enabling stable and site-specific conjugation of the scFv to diagnostic and therapeutic substrates. To enhance antigen …
-
Development of potential immunodiagnostic & therapeutic techniques using SNAP-fusion proteins as tools for the validation of Triple-negative Breast Cancer
… the following tumour associated antigens (TAAs): CSPG4 (a transmembrane protein found in 50% of TNBC cases), EGFR (which is overexpressed in 13-76% of TNBCs), and MSLN (which is overexpressed in 67% of TNBCs) as potential targets for monospecific therapy. The evolution of antibody-based …
-
Optimization of a pericyte therapy to improve muscle recovery following hindlimb immobilization
… surface markers, such as neural/glial antigen 2 (Cspg4/NG2), melanoma cell adhesion molecule (Mcam/CD146), and platelet-derived growth factor receptor β (PDGFRβ). Currently, none of these markers are uniquely expressed by pericytes; therefore, cell heterogeneity likely exists when isolating based …
-
Evaluation of tumour-associated antigens to optically label cutaneous basal cell carcinoma for surgical excision
… cells. The specific binding to EpCAM, EMA, CSPG4, and CD138 antigenexpressing cell lines was observed on incubation with scFvUBS54-SNAP-tag, scFvID405- SNAP-tag, 9.2.27scFv-SNAP-tag, and scFvh-STL002-SNAP-tag, respectively. In addition, we showed the selective cell killing effect of …
-
Development of SNAP-tag based fusion proteins as novel auristatin F-containing immunoconjugates and photoimmunotheranostics in the detection and treatment of triple-negative breast cancer
… for chondroitin sulfate proteoglycan 4 (CSPG4), CD44 and aspartate (aspartyl/asparaginyl) β-hydroxylase (ASPH)-positive TNBC cells, (2) generate functional recombinant ADC formulations as robust delivery systems carrying the antimitotic drug monomethyl auristatin F (MMAF/AURIF), …